How do arbs work
Pro Research Analysisby 
Searched over 200M research papers
Understanding the Mechanisms and Applications of ARBs
Introduction to ARBs: Angiotensin II Receptor Blockers
Angiotensin II receptor blockers (ARBs) are a class of medications primarily used to manage hypertension and reduce cardiovascular disease risk. They function by selectively inhibiting the AT1 subtype of the angiotensin II receptors, which play a crucial role in the renin-angiotensin-aldosterone system (RAAS) . This inhibition helps in lowering blood pressure and has various other therapeutic benefits.
Mechanism of Action: How ARBs Work
ARBs work by blocking the binding of angiotensin II to the AT1 receptor. Angiotensin II is a potent vasoconstrictor, meaning it narrows blood vessels, which increases blood pressure. By preventing this binding, ARBs cause blood vessels to relax and widen, thereby lowering blood pressure . This mechanism also reduces the secretion of aldosterone, a hormone that causes the kidneys to retain sodium and water, further contributing to blood pressure reduction .
Cardiovascular Benefits of ARBs
Efficacy in Reducing Cardiovascular Events
ARBs have demonstrated significant efficacy in reducing cardiovascular events and mortality across various patient populations. Studies have shown that ARBs are effective in both primary prevention (e.g., patients with hypertension and left-ventricular hypertrophy) and secondary prevention (e.g., post-myocardial infarction patients) . For instance, the LIFE study highlighted the benefits of ARBs in patients with hypertension, while the VALIANT study showed their effectiveness in post-MI patients .
Comparison with ACE Inhibitors
Some studies have indicated that ARBs are statistically equivalent to ACE inhibitors in certain populations, such as post-MI patients and those with vascular disease or diabetes . However, a meta-analysis suggested that while ARBs may have a small benefit in terms of stroke risk, they do not confer the same level of cardiovascular protection as ACE inhibitors in non-heart failure patients .
ARBs and Cancer Risk
Controversial Findings on Cancer Risk
The relationship between ARBs and cancer risk has been a subject of debate. A meta-analysis indicated a modestly increased risk of new cancer diagnoses among patients using ARBs, particularly lung cancer . However, another systematic review found that ARBs could decrease lung cancer risk, suggesting that the overall impact of ARBs on cancer risk remains inconclusive and warrants further investigation .
Enhancing Cancer Immunotherapy
Recent research has explored the potential of ARBs in cancer treatment beyond their cardiovascular benefits. ARBs can reprogram cancer-associated fibroblasts (CAFs) to a quiescent state, reducing immunosuppression and enhancing the efficacy of cancer immunotherapy. This effect is amplified when ARBs are chemically linked to polymers that degrade selectively in the acidic microenvironment of tumors, thereby minimizing systemic side effects .
Conclusion
ARBs are a versatile class of medications with proven benefits in managing hypertension and reducing cardiovascular events. While their role in cancer risk remains debated, ongoing research continues to explore their potential in enhancing cancer immunotherapy. The broad spectrum of applications and ongoing studies highlight the importance of ARBs in both cardiovascular and oncological therapeutics.
Sources and full results
Most relevant research papers on this topic